|
|
|
| home > white papers > Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor - Eppendorf |
|
|
 WHITE PAPERS |
|
Eppendorf
|
|
Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor
|
|
The number of bioprocess applications for microalgae has increased in
recent years, particularly in the fi eld of biofuel production. The
combination of the New Brunswick CelliGen 310 stirred-tank bioreactor
and the DASGIP LED Illumination System creates a bioreactor setup which
is capable of supporting high density microalgal growth. Using the
stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and
intensities can be controlled for optimal support of all types of
chlorophylls and carotenoids. For this study in which high density
culture of up to 1.5 x 107 cells/mL was achieved, the unicellular
freshwater alga, Dunaliella tertiolecta, was used.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Micro dosing pumps in global use against COVID-19
(PresseBox) ( Schwerin, 24.06.20 ) Automated analysis devices are the
essential basis for extensive test capacities for the corona virus.
Through parallel and faster processes, automation significantly
increases the number of tests, saves manpower and ensures process
reliability. For sample preparation for SARS-CoV-2, a few microliters of
a solution of chemicals and enzymes are dosed. Micro annular gear pumps
of the low pressure series from HNP Mikrosysteme perform this demanding
task with highest precision and process reliability. The minimum dosing
quantity is 0.25 µl, the pumps have a very small footprint and can be
easily integrated into control systems. Fully automated analysis devices
can contain up to sixteen dosing pumps and can handle up to 4,000
samples in 24 hours.
More info >> |
|
 |
White Papers |
 |
|
Device Develop for Combo Products
Phillips-Medisize
Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Europe
18-21 October 2020, Barcelona, Spain
The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >> |
|
|
|
